2m 2m 2m 2m 2m 2m 2m
ROYAL PHARM -A (RPRX)
NASDAQ
$55.08+$1.51 (+2.82%)
Price as of Jun 23, 2026 6:03 PM EDT- $23.7BMarket Cap
- 54.58%1-Year Change
- BiotechnologyIndustry
ROYAL PHARM -A (RPRX)
$55.08+$1.51 (+2.82%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 2.3B -0.11% | 2.3B -3.86% | 2.4B +5.24% | 2.2B -2.28% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 2.3B -0.11% | 2.3B -3.86% | 2.4B +5.24% | 2.2B -2.28% | |
Sales and Marketing Expense | 115.7M -38.65% | 188.6M -7.82% | 204.6M N/A | N/A N/A | |
Research and Development Expense | -452.0M +22,500.00% | -2.0M -96.15% | -52.0M -70.64% | -177.1M -11.48% | |
Depreciation and Amortization Expense | 3.9M N/A | 0 N/A | 0 -100.00% | 5.7M -75.34% | |
Total Operating Expenses | 818.7M -15.70% | 971.1M +12.61% | 862.4M -55.32% | 1.9B +124.76% | |
Operating Profit | 1.6B +20.66% | 1.3B -13.38% | 1.5B +385.94% | 307.1M -78.54% | |
Interest Income | 33.6M -29.05% | 47.3M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -187.2M -0.41% | -188.0M +13.13% | |
Interest Income and Expense and Net | 33.6M -29.05% | 47.3M +125.29% | -187.2M -0.41% | -188.0M +29.15% | |
Total Nonoperating Income and Expense | -235.3M -713.32% | 38.4M -81.55% | 207.9M +370.05% | -77.0M -59.37% | |
Income before Taxes | 1.3B -0.50% | 1.3B -21.72% | 1.7B +638.96% | 230.1M -81.46% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | 0 N/A | 0 -100.00% | 615.8M N/A | |
Net Income | 770.9M -10.25% | 859.0M -24.31% | 1.1B +2,549.50% | 42.8M -93.09% | |
Net Income from Continuing Operations Applicable to Common | 1.3B -0.50% | 1.3B -21.72% | 1.7B +638.96% | 230.1M -81.46% | |
Basic EPS and Net Income | 1.79 -6.77% | 1.92 -24.41% | 2.54 +2,440.00% | 0.10 -93.29% | |
Diluted EPS and Net Income | 1.78 -6.81% | 1.91 -24.51% | 2.53 +2,430.00% | 0.10 -93.29% | |
Basic Weighted Average Shares | 429.8M -4.10% | 448.2M +0.13% | 447.6M +2.20% | 438.0M +5.59% | |
Diluted Weighted Average Shares | 564.5M -4.99% | 594.1M -1.46% | 602.9M +37.66% | 438.0M +5.59% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 618.7M -33.40% | 929.0M +94.76% | 477.0M -72.12% | 1.7B +11.01% | |
Short-Term Investments | 18.8M -67.70% | 58.2M +218.03% | 18.3M +1,307.69% | 1.3M -98.03% | |
Cash and Cash Equivalents and Short-Term Investments | 637.5M -35.43% | 987.2M +99.31% | 495.3M -71.07% | 1.7B +6.53% | |
Total Current Assets | 1.5B -15.21% | 1.8B +41.43% | 1.3B -50.13% | 2.6B -11.23% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Assets | 79.3M +136.46% | 33.5M +414.17% | 6.5M -77.99% | 29.6M +614.81% | |
Total Assets | 19.6B +7.67% | 18.2B +11.24% | 16.4B -2.57% | 16.8B -4.01% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 380.0M -61.92% | 997.8M N/A | 0 -100.00% | 1.1B +912.02% | |
Total Current Liabilities | 636.2M -49.25% | 1.3B +676.82% | 161.4M -86.17% | 1.2B +581.33% | |
Total Long-Term Debt | 8.6B +29.57% | 6.6B +7.81% | 6.1B +0.27% | 6.1B -13.77% | |
Total Long-Term Liabilities | 120.8M +900.36% | 12.1M +1,242.22% | 900,000 -64.00% | 2.5M -99.96% | |
Total Liabilities | 9.9B +25.70% | 7.9B +25.13% | 6.3B -13.59% | 7.3B +0.29% | |
Retained Earnings | 2.4B -17.20% | 2.8B +13.03% | 2.5B +28.14% | 2.0B -12.88% | |
Total Stockholders Equity | 9.7B -6.07% | 10.3B +2.56% | 10.1B +5.87% | 9.5B -7.06% | |
Total Shares Outstanding | 428.7M -27.24% | 589.2M -1.39% | 597.5M -1.61% | 607.3M +0.008% | |
Cash Flow | |||||
Cash from Operating Activities | 2.5B -10.08% | 2.8B -7.32% | 3.0B +39.36% | 2.1B +6.27% | |
Capital Expenditures | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Investing Activities | -1.6B -39.73% | -2.7B +29.20% | -2.1B +101.35% | -1.0B -44.96% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -1.2B -428.39% | 361.1M +116.81% | -2.1B +127.42% | -944.9M -345.35% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | 68.97% +20.79% | 57.10% -9.90% | 63.37% +361.72% | 13.73% -78.04% | |
Return on Assets | 4.07% -17.93% | 4.96% -27.39% | 6.84% +2,640.40% | 0.25% -93.25% | |
Return on Equity | 7.69% -8.60% | 8.41% -27.33% | 11.57% +2,571.79% | 0.43% -92.96% | |
Revenue Growth | -0.11% -97.23% | -3.86% -173.67% | 5.24% +329.83% | -2.28% -128.98% | |
Current Ratio | 2.40 +67.08% | 1.44 -81.79% | 7.90 +260.59% | 2.19 -86.97% | |
Cash Ratio | 0.97 +31.22% | 0.74 -74.93% | 2.96 +101.60% | 1.47 -83.71% | |
Debt-to-Equity Ratio | 0.92 +25.19% | 0.74 +20.97% | 0.61 -19.63% | 0.76 +7.70% | |
Debt-to-Assets Ratio | 0.46 +9.22% | 0.42 +11.54% | 0.37 -12.68% | 0.43 +4.28% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow